Teva OK'd for AZ's Symbicort generic; Sun OK'd for generic of Roche's Boniva; Endocrine Society warns about testosterone enhancers;

Pharma News

@FiercePharma: ICYMI: WHO reports success in distributing vaccines at ambient temperatures. Story via FierceVaccines. | Follow @FiercePharma

@EricPFierce: GSK could get some financial breathing room with an EU nod for Anoro. Story | Follow @EricPFierce

@CarlyHFierce: Tops on the old FP site yesterday: Reuters: Bayer, Novartis, Reckitt eye $10B-$12B bids for Merck consumer unit. Story  | Follow @CarlyHFierce

> Frost & Sullivan is predicting fast growth of diabetes drugs in Latin America. Story

> Teva Pharmaceutical Industries ($TEVA) has gotten EU approval for a generic that will put pressure on AstraZeneca's blockbuster Symbicort. Story

> Novartis ($NVS) has won approval of its eye drug Lucentis for a fourth indication in Japan. Release

> The Endocrine Society has issued a statement saying men should understand the risks of taking testosterone-raising drugs and pointing out that low testosterone is not a disease, only a number. Story

> Bank of America Merrill Lynch and Mizuho Bank are leading the $7 billion financing behind Actavis' ($ACT) acquisition of Forest Laboratories. ($FRX). Story

> India's Sun Pharma has gotten FDA approval to make a generic of Roche's osteoporosis drug Boniva, the first drugmaker to get an OK for the product. Item

Medical Device News

@FierceMedDev: At J&J's Coridis, at least, renal denervation is continuing to advance. Press release. | Follow @FierceMedDev

@MarkHFierce: I spoke to Daktari Diagnostics' CEO about the company's Series D fundraising efforts. Story via FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: BioMérieux's BioFire sets course for GI panel FDA clearance. Article | Follow @MichaelGFierce

@GalenMoore: Sham surgeries: Medtech's placebos? Or a waste of money at patients' risk? via Forbes | Follow @GalenMoore

> Myriad touts positive data for Dx that predicts prostate cancer recurrence. More

> Wall Street cools to CryoLife's new guidance. Story

Biotech News

@FierceBiotech: Belgian UCB gets ready for CEO change plus more career changes in biopharma in this week's Chutes & Ladders. | Follow @FierceBiotech

@JohnCFierce: Merck KGaA has the firepower to pull off a big buyout, but will it? Story | Follow @JohnCFierce

@DamianFierce: Ariad's new board member is an activist investor with a history of pushing companies to sell. More | Follow @DamianFierce

@EmilyMFierce: Gene therapy regenerates damaged tissue in pigs after heart attack. Story from FierceBiotech Research | Follow @EmilyMFierce

> EU breathes hope into GlaxoSmithKline's latest respiratory contender. Article

> Isis gears up for Phase III with Biogen-partnered antisense drug. News

And Finally... There has been an upsurge this year in young adults and middle-aged people getting the flu in the U.S., and dying from it, even after vaccine makers have brought a host of new products to market. Story

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.